2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

J. Vansteenkiste; L. Crinò; C. Dooms; J. Y. Douillard; C. Faivre-Finn; E. Lim; G. Rocco; S. Senan; P. van Schil; G. Veronesi; R. Stahel; S. Peters; E. Felip; Keith Kerr; Benjamin Besse; Wilfried Eberhardt; Martin Edelman; Tony Mok; Ken O'Byrne; Silvia Novello; Lukas Bubendorf; Antonio Marchetti; Paul Baas; Martin Reck; Konstantinos Syrigos; Luis Paz-Ares; Egbert F. Smit; Peter Meldgaard; Alex Adjei; Marianne Nicolson; Walter Weder; Dirk de Ruysscher; Cecile Le Pechoux; Paul de Leyn; Virginie Westeel

doi:10.1093/annonc/mdu089

2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

J. Vansteenkiste, L. Crinò, C. Dooms, J. Y. Douillard, C. Faivre-Finn, E. Lim, G. Rocco, S. Senan, P. van Schil, G. Veronesi, R. Stahel, S. Peters, E. Felip, Keith Kerr, Benjamin Besse, Wilfried Eberhardt, Martin Edelman, Tony Mok, Ken O'Byrne, Silvia NovelloLukas Bubendorf, Antonio Marchetti, Paul Baas, Martin Reck, Konstantinos Syrigos, Luis Paz-Ares, Egbert F. Smit, Peter Meldgaard, Alex Adjei, Marianne Nicolson, Walter Weder, Dirk de Ruysscher, Cecile Le Pechoux, Paul de Leyn, Virginie Westeel

Applied Medicine

Research output: Contribution to journal › Article › peer-review

388 Citations (Scopus)

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11–12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.

Original language	English
Article number	mdu089
Pages (from-to)	1462-1474
Number of pages	13
Journal	Annals of Oncology
Volume	25
Issue number	8
Early online date	20 Feb 2014
DOIs	https://doi.org/10.1093/annonc/mdu089
Publication status	Published - 1 Aug 2014

Bibliographical note

funding
All costs relating to the consensus conference were covered from the European Society for Medical Oncology central funds. There was no external funding of the event or the manuscript production.

Keywords

Consensus
Early disease
ESMO
Lung cancer
Non-small-cell lung cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdu089Licence: Unspecified

Cite this

Vansteenkiste, J., Crinò, L., Dooms, C., Douillard, J. Y., Faivre-Finn, C., Lim, E., Rocco, G., Senan, S., van Schil, P., Veronesi, G., Stahel, R., Peters, S., Felip, E., Kerr, K., Besse, B., Eberhardt, W., Edelman, M., Mok, T., O'Byrne, K., ... Westeel, V. (2014). 2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 25(8), 1462-1474. Article mdu089. https://doi.org/10.1093/annonc/mdu089

Vansteenkiste, J, Crinò, L, Dooms, C, Douillard, JY, Faivre-Finn, C, Lim, E, Rocco, G, Senan, S, van Schil, P, Veronesi, G, Stahel, R, Peters, S, Felip, E, Kerr, K, Besse, B, Eberhardt, W, Edelman, M, Mok, T, O'Byrne, K, Novello, S, Bubendorf, L, Marchetti, A, Baas, P, Reck, M, Syrigos, K, Paz-Ares, L, Smit, EF, Meldgaard, P, Adjei, A, Nicolson, M, Weder, W, de Ruysscher, D, Le Pechoux, C, de Leyn, P & Westeel, V 2014, '2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up', Annals of Oncology, vol. 25, no. 8, mdu089, pp. 1462-1474. https://doi.org/10.1093/annonc/mdu089

@article{33b4e1d05ae24afb9aafe5d93a119759,

title = "2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up",

abstract = "To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11–12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.",

keywords = "Consensus, Early disease, ESMO, Lung cancer, Non-small-cell lung cancer",

author = "J. Vansteenkiste and L. Crin{\`o} and C. Dooms and Douillard, {J. Y.} and C. Faivre-Finn and E. Lim and G. Rocco and S. Senan and {van Schil}, P. and G. Veronesi and R. Stahel and S. Peters and E. Felip and Keith Kerr and Benjamin Besse and Wilfried Eberhardt and Martin Edelman and Tony Mok and Ken O'Byrne and Silvia Novello and Lukas Bubendorf and Antonio Marchetti and Paul Baas and Martin Reck and Konstantinos Syrigos and Luis Paz-Ares and Smit, {Egbert F.} and Peter Meldgaard and Alex Adjei and Marianne Nicolson and Walter Weder and {de Ruysscher}, Dirk and {Le Pechoux}, Cecile and {de Leyn}, Paul and Virginie Westeel",

note = "funding All costs relating to the consensus conference were covered from the European Society for Medical Oncology central funds. There was no external funding of the event or the manuscript production.",

year = "2014",

month = aug,

day = "1",

doi = "10.1093/annonc/mdu089",

language = "English",

volume = "25",

pages = "1462--1474",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - 2nd ESMO consensus conference on lung cancer

T2 - Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

AU - Vansteenkiste, J.

AU - Crinò, L.

AU - Dooms, C.

AU - Douillard, J. Y.

AU - Faivre-Finn, C.

AU - Lim, E.

AU - Rocco, G.

AU - Senan, S.

AU - van Schil, P.

AU - Veronesi, G.

AU - Stahel, R.

AU - Peters, S.

AU - Felip, E.

AU - Kerr, Keith

AU - Besse, Benjamin

AU - Eberhardt, Wilfried

AU - Edelman, Martin

AU - Mok, Tony

AU - O'Byrne, Ken

AU - Novello, Silvia

AU - Bubendorf, Lukas

AU - Marchetti, Antonio

AU - Baas, Paul

AU - Reck, Martin

AU - Syrigos, Konstantinos

AU - Paz-Ares, Luis

AU - Smit, Egbert F.

AU - Meldgaard, Peter

AU - Adjei, Alex

AU - Nicolson, Marianne

AU - Weder, Walter

AU - de Ruysscher, Dirk

AU - Le Pechoux, Cecile

AU - de Leyn, Paul

AU - Westeel, Virginie

N1 - funding All costs relating to the consensus conference were covered from the European Society for Medical Oncology central funds. There was no external funding of the event or the manuscript production.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11–12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.

AB - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11–12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.

KW - Consensus

KW - Early disease

KW - ESMO

KW - Lung cancer

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84904545741&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu089

DO - 10.1093/annonc/mdu089

M3 - Article

C2 - 24562446

AN - SCOPUS:84904545741

SN - 0923-7534

VL - 25

SP - 1462

EP - 1474

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

M1 - mdu089

ER -

2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this